Correlation Between VistaGen Therapeutics and Virpax Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both VistaGen Therapeutics and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining VistaGen Therapeutics and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between VistaGen Therapeutics and Virpax Pharmaceuticals, you can compare the effects of market volatilities on VistaGen Therapeutics and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in VistaGen Therapeutics with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of VistaGen Therapeutics and Virpax Pharmaceuticals.

Diversification Opportunities for VistaGen Therapeutics and Virpax Pharmaceuticals

0.78
  Correlation Coefficient

Poor diversification

The 3 months correlation between VistaGen and Virpax is 0.78. Overlapping area represents the amount of risk that can be diversified away by holding VistaGen Therapeutics and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and VistaGen Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on VistaGen Therapeutics are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of VistaGen Therapeutics i.e., VistaGen Therapeutics and Virpax Pharmaceuticals go up and down completely randomly.

Pair Corralation between VistaGen Therapeutics and Virpax Pharmaceuticals

Given the investment horizon of 90 days VistaGen Therapeutics is expected to generate 0.4 times more return on investment than Virpax Pharmaceuticals. However, VistaGen Therapeutics is 2.51 times less risky than Virpax Pharmaceuticals. It trades about -0.1 of its potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about -0.14 per unit of risk. If you would invest  273.00  in VistaGen Therapeutics on September 25, 2024 and sell it today you would lose (23.00) from holding VistaGen Therapeutics or give up 8.42% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

VistaGen Therapeutics  vs.  Virpax Pharmaceuticals

 Performance 
       Timeline  
VistaGen Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days VistaGen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Virpax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

VistaGen Therapeutics and Virpax Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with VistaGen Therapeutics and Virpax Pharmaceuticals

The main advantage of trading using opposite VistaGen Therapeutics and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if VistaGen Therapeutics position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.
The idea behind VistaGen Therapeutics and Virpax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
CEOs Directory
Screen CEOs from public companies around the world